MedUni Vienna: contextflow receives funding from European Innovation Council Accelerator Programme

MedUni Vienna start-up the only Austrian company among those selected

The joint spin-off of the Medical University of Vienna, the TU Wien and the European research project Khresmoi "contextflow" is the only Austrian company to be supported by the European Innovation Council's Accelerator funding programme.

contextflow is one of 51 companies to receive funding or investment from the European Innovation Council Accelerator Programme. A total of 260 million euros in grants and equity investments will be distributed and paid out over the next two to three months. The selected companies are geographically spread across 17 countries, with contextflow being the only one from Austria.

The EIC Accelerator Programme offers support to start-ups and small and medium-sized enterprises in the form of grants of up to €2.5 million and equity investments of up to €15 million or more. Funded companies also benefit from Business Acceleration Services, which provide access to world-class expertise, potential business partners and investors.

Contextflow develops algorithms that use deep learning models to support the diagnosis and quantification of radiological images. The software, which is already in clinical use in many European countries, analyses computed tomography images and is an important aid in the early detection and treatment of cancer, for example, or in the assessment of interstitial lung disease. The funding will enable contextflow to further develop its technology to improve medical imaging. The start-up's goal is to increase the accuracy and efficiency of medical image analysis through the use of artificial intelligence.

About "contextflow"

contextflow is a spin-off of the Medical University of Vienna, the TU Wien and the European research project Khresmoi. The company was founded in 2016 by a team of AI and medical image processing experts at the University Department of Radiology and Nuclear Medicine, Computational Imaging Research Lab.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)